Ezetimibe and MK-677 Interaction

Avoid
Mechanism-based 64% confidence

Ezetimibe and MK-677 have a potentially harmful interaction with 64% confidence. Both Ezetimibe and MK-677 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. These compounds primarily affect different organ systems.

Compound Profiles

Ezetimibe

Cholesterol Absorption Inhibitor | Lipid Management On Cycle

Ezetimibe selectively inhibits the NPC1L1 transporter protein located on the luminal surface of enterocytes in the jejunum of the small intestine. NPC1L1 is the critical gateway for intestinal cholesterol absorption, responsible for uptaking both dietary cholesterol and the much larger pool of biliary cholesterol that is recirculated through the enterohepatic cycle.

Half-life: ~22 hours Typical dose: 10 mg/day cardiovascular
npc1l1 hepatotoxiclipid disruptingteratogenic
View full profile

MK-677

Ghrelin Receptor Agonist | Oral Growth Hormone Secretagogue

Selectively binds GHS-R1a receptors in hypothalamus and pituitary, triggering pulsatile growth hormone release while maintaining natural circadian patterns..

Half-life: ~24 hours Typical dose: Start 12.5mg daily, increase to 25mg based on tolerance growth hormone, weight loss, sleep
ghrelin receptor blood pressure raisingcarcinogenic riskhepatotoxicinsulin disrupting
View full profile

Combined Organ Load

Heart
low
Brain
low
GI Tract
low
Pituitary
low

Shared Safety Flags

2x 2 hepatotoxic compounds (Ezetimibe, MK-677). Liver damage risk significantly increased. Include liver support (TUDCA/NAC) and monitor ALT/AST.
2x 2 compounds share the teratogenic safety flag (Ezetimibe, MK-677). Monitor accordingly.

Frequently Asked Questions

Can I take Ezetimibe with MK-677?

Combining Ezetimibe with MK-677 is not recommended. Both Ezetimibe and MK-677 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.

Is Ezetimibe and MK-677 safe together?

This combination carries significant risk. Both Ezetimibe and MK-677 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.

What are the interactions between Ezetimibe and MK-677?

Both Ezetimibe and MK-677 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 64% confidence and is inferred from pharmacological mechanism analysis.

How should I time Ezetimibe and MK-677?

Ezetimibe has a half-life of ~22 hours and MK-677 has a half-life of ~24 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: Ezetimibe vs MK-677

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.